Lukas Westermann
Overview
Explore the profile of Lukas Westermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westermann L, Nolde J, Wiegel J, Buchler G, Arnold F, Welte T
Am J Nephrol
. 2025 Feb;
:1-15.
PMID: 40010320
Introduction: Maintaining renin-angiotensin-aldosterone system inhibition (RAASi) in advanced chronic kidney disease (CKD) to delay CKD progression is still controversial. This is due to potential side effects associated with RAASi, such...
2.
Busch T, Neubauer B, Schmitt L, Cascante I, Knoblich L, Wegehaupt O, et al.
FASEB J
. 2024 Nov;
38(21):e70162.
PMID: 39530576
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2, encoding polycystin-1 (PC1) and polycystin-2 (PC2), which are required for the regulation of the renal tubular...
3.
Arnold F, Kappes J, Rottmann F, Westermann L, Welte T
J Intern Med
. 2023 Nov;
295(2):206-215.
PMID: 37925625
Background: Diabetes mellitus is a major risk factor for the development of chronic kidney disease (CKD). There is limited data addressing the value of glycated hemoglobin (HbA1c) to predict renal...
4.
Westermann L, Rottmann F, Hug M, Staudacher D, Wobser R, Arnold F, et al.
BMC Nephrol
. 2023 Sep;
24(1):260.
PMID: 37661268
No abstract available.
5.
Westermann L, Rottmann F, Hug M, Staudacher D, Wobser R, Arnold F, et al.
BMC Nephrol
. 2023 Aug;
24(1):235.
PMID: 37563703
Background: Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification...
6.
Welte T, Westermann L, Kappes J, Schramm M, Bemtgen X, Staudacher D, et al.
Arthritis Rheumatol
. 2023 Jun;
75(11):2045-2053.
PMID: 37276446
Objective: B-cell depletion using the anti-CD20 monoclonal antibody rituximab is a cornerstone in the therapeutic concept of multiple autoimmune diseases. B-cell depletion is associated with a higher risk for severe...
7.
Welte T, Arnold F, Westermann L, Rottmann F, Hug M, Neumann-Haefelin E, et al.
BMC Nephrol
. 2023 Jan;
24(1):8.
PMID: 36631797
Background: C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may...
8.
Westermann L, Li Y, Gocmen B, Niedermoser M, Rhein K, Jahn J, et al.
Sci Rep
. 2022 Oct;
12(1):18211.
PMID: 36307508
Genome editing tools such as CRISPR/Cas9 enable the rapid and precise manipulation of genomes. CRISPR-based genome editing has greatly simplified the study of gene function in cell lines, but its...
9.
Arnold F, Wobser R, Kalbhenn J, Westermann L
Artif Organs
. 2022 May;
46(9):1847-1855.
PMID: 35490349
Background: Severe COVID-19 can necessitate multiple organ support including veno-venous extracorporeal membrane oxygenation (vvECMO) and renal replacement therapy. The therapy can be complicated by venous thromboembolism due to COVID-19-related hypercoagulability,...
10.
Westermann L, Neubauer B, Kottgen M
Pflugers Arch
. 2020 Nov;
473(1):1-2.
PMID: 33244639
No abstract available.